P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM ANALYSIS

• H. Quach,
• M. Gironella,
• C. Lee,
• R. Popat,
• P. Cannell,
• R. S. Kasinathan,
• B. Chopra,
• R. Rogers,
• G. Ferron-Brady,
• S. Shafi-Harji,
• N. Patel,
• J. Opalinska,
• I. Gupta,
• B. Augustson

Affiliations

H. Quach

1 University of Melbourne, St. Vincent’s Hospital Melbourne, Melbourne, Australia

M. Gironella

2 Department of Hematology, University Hospital Vall d’Hebron, Barcelona, Spain

C. Lee

3 Royal Adelaide Hospital, Adelaide, Australia

R. Popat

4 NIHR UCLH Clinical Research Facility, University College London Hospitals, NHS Foundation Trust, London, United Kingdom

P. Cannell

5 Department of Medicine, Royal Perth Hospital, Perth, Australia

R. S. Kasinathan

6 GlaxoSmithKline, Upper Providence, PA, United States of America

B. Chopra

7 GlaxoSmithKline, London

R. Rogers

6 GlaxoSmithKline, Upper Providence, PA, United States of America

G. Ferron-Brady

6 GlaxoSmithKline, Upper Providence, PA, United States of America

S. Shafi-Harji

8 GlaxoSmithKline, Stevenage, United Kingdom

N. Patel

7 GlaxoSmithKline, London

J. Opalinska

6 GlaxoSmithKline, Upper Providence, PA, United States of America

I. Gupta

6 GlaxoSmithKline, Upper Providence, PA, United States of America

B. Augustson

9 Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia